<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Methimazole acts faster than PTU in Graves' hyperthyroidism</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Methimazole acts faster than PTU in Graves' hyperthyroidism</h1>
<div class="graphic"><div class="figure"><div class="ttl">Methimazole acts faster than PTU in Graves' hyperthyroidism</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Time required for patients with Graves' hyperthyroidism to become euthyroid (normal serum T4 and T3 concentrations) after therapy with methimazole (10 mg three times daily, n = 66) or PTU (100 mg three times daily, n = 17). The euthyroid state was achieved more quickly with methimazole (5.8 versus 16.8 weeks).</div><div class="graphic_footnotes">PTU: propylthiouracil; T4: thyroxine; T3: triiodothyronine.</div><div class="graphic_reference">Data from: Okamura K, Ikenoue H, Shiroozu A, et al. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1987; 65:719.</div><div id="graphicVersion">Graphic 54732 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
